Vosoritide - BioMarin Pharmaceutical
Alternative Names: BMN-111; Modified C-natriuretic peptide - BioMarin Pharmaceutical; Modified recombinant human C-type natriuretic peptide - BioMarin Pharmaceutical; ProCNP38; VOXZOGOLatest Information Update: 20 Jun 2024
At a glance
- Originator BioMarin Pharmaceutical
- Class Cyclic peptides; Natriuretic agents; Natriuretic peptides; Recombinant proteins
- Mechanism of Action Atrial natriuretic factor receptor B agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Achondroplasia
- Phase II Short stature
Most Recent Events
- 17 Jun 2024 Efficacy data from the phase II 111-205 trial in Achondroplasia was released by BioMarin
- 17 Jun 2024 BioMarin Pharmaceutical plans multiple clinical trials in Turner's syndrome and Noonan syndrome later this year
- 29 Apr 2024 BioMarin plans a phase II trial for Short stature (In children) in September 2024 (Injection) (NCT06382155)